In the present study, we aimed to discover new diagnostic biomarkers to distinguish AFP-negative HCC from LC patients based on glycoproteomic technology and confirmed the differential expression of the identified glycopeptides in a validation set. This evidence concerns the gene AFP and laryngotracheoesophageal cleft.